MX2016006688A - Inhibidores tetraciclicos de autotaxina. - Google Patents
Inhibidores tetraciclicos de autotaxina.Info
- Publication number
- MX2016006688A MX2016006688A MX2016006688A MX2016006688A MX2016006688A MX 2016006688 A MX2016006688 A MX 2016006688A MX 2016006688 A MX2016006688 A MX 2016006688A MX 2016006688 A MX2016006688 A MX 2016006688A MX 2016006688 A MX2016006688 A MX 2016006688A
- Authority
- MX
- Mexico
- Prior art keywords
- tetracyclic
- compounds
- autotaxin inhibitors
- autotaxin
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se describen compuestos que son inhibidores de autotaxina, métodos para elaborar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden dichos compuestos, y métodos para utilizar dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos asociados con actividad autotaxina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907947P | 2013-11-22 | 2013-11-22 | |
US201462038093P | 2014-08-15 | 2014-08-15 | |
PCT/US2014/066705 WO2015077502A1 (en) | 2013-11-22 | 2014-11-20 | Tetracyclic autotaxin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006688A true MX2016006688A (es) | 2016-11-29 |
Family
ID=53180151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006688A MX2016006688A (es) | 2013-11-22 | 2014-11-20 | Inhibidores tetraciclicos de autotaxina. |
Country Status (18)
Country | Link |
---|---|
US (2) | US9926318B2 (es) |
EP (1) | EP3071569A4 (es) |
JP (1) | JP2016537388A (es) |
KR (1) | KR20160088878A (es) |
CN (1) | CN105764903B (es) |
AU (1) | AU2014352887A1 (es) |
BR (1) | BR112016010221A2 (es) |
CA (1) | CA2930735A1 (es) |
CL (1) | CL2016001232A1 (es) |
CR (1) | CR20160290A (es) |
EA (1) | EA201690880A1 (es) |
HK (1) | HK1226074B (es) |
IL (1) | IL245389A0 (es) |
MX (1) | MX2016006688A (es) |
NI (1) | NI201600070A (es) |
PE (1) | PE20160902A1 (es) |
PH (1) | PH12016500863A1 (es) |
WO (1) | WO2015077502A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016530209A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア,インク. | ビニルオートタキシン阻害剤化合物 |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
CA2930735A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Tetracyclic autotaxin inhibitors |
HUE055213T2 (hu) | 2013-11-22 | 2021-11-29 | Sabre Therapeutics Llc | Autotaxin inhibitor vegyületek |
AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
CN110128425B (zh) * | 2015-07-11 | 2021-09-07 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的芳环或杂环取代的稠合喹啉化合物 |
CN105021735B (zh) * | 2015-07-21 | 2017-09-19 | 中国科学院西北高原生物研究所 | 白刺种子或其提取物中ss和rsMTCA的检测方法 |
WO2023060022A1 (en) * | 2021-10-05 | 2023-04-13 | Turning Point Therapeutics, Inc. | Synthesis of macrocyclic compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
AU2002213421A1 (en) | 2000-10-03 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
WO2010040080A1 (en) | 2008-10-03 | 2010-04-08 | Abby Louise Parrill-Baker | Mechanism-based inactivators of autotaxin |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
CA2745041C (en) | 2008-12-01 | 2017-08-22 | Kai Schiemann | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
CA2757413C (en) | 2009-04-02 | 2017-01-10 | Merck Patent Gmbh | Heterocyclic compounds as autotaxin inhibitors |
CA2757368C (en) | 2009-04-02 | 2019-03-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
JP5779172B2 (ja) | 2009-04-02 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | オートタキシン阻害剤 |
WO2011002918A1 (en) | 2009-06-30 | 2011-01-06 | The University Of Memphis Research Foundation | Novel diverse lead compound autotaxin inhibitors |
DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
US9187471B2 (en) * | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
CN102822171B (zh) | 2010-03-26 | 2015-09-02 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的苯并萘啶胺类 |
ES2646834T3 (es) | 2010-08-20 | 2017-12-18 | Amira Pharmaceuticals, Inc. | Inhibidores de autotaxina y usos de los mismos |
WO2012100018A1 (en) | 2011-01-20 | 2012-07-26 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
US9035056B2 (en) * | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US8791132B2 (en) * | 2011-02-18 | 2014-07-29 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
WO2012166415A1 (en) | 2011-05-27 | 2012-12-06 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
JP2013129632A (ja) * | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Enpp2阻害化合物 |
WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
MX2015007936A (es) | 2012-12-19 | 2016-03-11 | Novartis Ag | Inhibidores de autotaxina. |
JP2016530209A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア,インク. | ビニルオートタキシン阻害剤化合物 |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
HUE055213T2 (hu) | 2013-11-22 | 2021-11-29 | Sabre Therapeutics Llc | Autotaxin inhibitor vegyületek |
CA2930735A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Tetracyclic autotaxin inhibitors |
US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
-
2014
- 2014-11-20 CA CA2930735A patent/CA2930735A1/en not_active Abandoned
- 2014-11-20 JP JP2016533529A patent/JP2016537388A/ja active Pending
- 2014-11-20 KR KR1020167014492A patent/KR20160088878A/ko not_active Application Discontinuation
- 2014-11-20 CN CN201480063882.4A patent/CN105764903B/zh not_active Expired - Fee Related
- 2014-11-20 BR BR112016010221A patent/BR112016010221A2/pt not_active Application Discontinuation
- 2014-11-20 EP EP14863158.3A patent/EP3071569A4/en not_active Withdrawn
- 2014-11-20 CR CR20160290A patent/CR20160290A/es unknown
- 2014-11-20 MX MX2016006688A patent/MX2016006688A/es unknown
- 2014-11-20 PE PE2016000667A patent/PE20160902A1/es not_active Application Discontinuation
- 2014-11-20 US US15/036,370 patent/US9926318B2/en active Active
- 2014-11-20 WO PCT/US2014/066705 patent/WO2015077502A1/en active Application Filing
- 2014-11-20 EA EA201690880A patent/EA201690880A1/ru unknown
- 2014-11-20 AU AU2014352887A patent/AU2014352887A1/en not_active Abandoned
-
2016
- 2016-05-02 IL IL245389A patent/IL245389A0/en unknown
- 2016-05-10 PH PH12016500863A patent/PH12016500863A1/en unknown
- 2016-05-20 NI NI201600070A patent/NI201600070A/es unknown
- 2016-05-20 CL CL2016001232A patent/CL2016001232A1/es unknown
- 2016-12-21 HK HK16114542A patent/HK1226074B/zh not_active IP Right Cessation
-
2018
- 2018-02-08 US US15/892,142 patent/US20180162859A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016537388A (ja) | 2016-12-01 |
EP3071569A1 (en) | 2016-09-28 |
PH12016500863A1 (en) | 2016-07-18 |
WO2015077502A1 (en) | 2015-05-28 |
IL245389A0 (en) | 2016-06-30 |
PE20160902A1 (es) | 2016-09-04 |
AU2014352887A1 (en) | 2016-06-09 |
HK1226074B (zh) | 2017-09-22 |
EA201690880A1 (ru) | 2016-12-30 |
CR20160290A (es) | 2016-09-28 |
US20160264575A1 (en) | 2016-09-15 |
US20180162859A1 (en) | 2018-06-14 |
CA2930735A1 (en) | 2015-05-28 |
CN105764903A (zh) | 2016-07-13 |
NI201600070A (es) | 2016-09-21 |
KR20160088878A (ko) | 2016-07-26 |
BR112016010221A2 (pt) | 2018-05-02 |
CN105764903B (zh) | 2018-09-18 |
CL2016001232A1 (es) | 2017-02-03 |
EP3071569A4 (en) | 2017-09-13 |
US9926318B2 (en) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
MY187540A (en) | Compounds active towards bromodomains | |
MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
PH12017501979A1 (en) | Pharmaceutical compound | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
MX2017001512A (es) | Compuestos activos hacia bromodominios. |